Outlook Therapeutics delays Q2 Form 10-Q filing after finance staff turnover
OTLK•Form 12b-25 filed to delay quarterly report
Outlook Therapeutics filed a Form 12b-25 to delay its quarterly Form 10-Q for the period ended June 30, 2026.
The filing cited finance staff turnover, limited internal resources, and time spent on a public offering that closed Aug. 14, 2026.
The company expects to file the Form 10-Q by the fifth calendar day after the original due date.
The notice indicated no significant change in results of operations versus the prior-year comparable period.
